Skip to main content
Clinical Trials/NCT02946840
NCT02946840
Completed
Not Applicable

The Use of a New Core Needle in the Endoscopic Ultrasound Assisted Tissue Sampling for Pancreatic Solid Masses

Istituto Clinico Humanitas1 site in 1 country100 target enrollmentAugust 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pancreatic Masses
Sponsor
Istituto Clinico Humanitas
Enrollment
100
Locations
1
Primary Endpoint
Core acquisition
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) is a reliable, safe, and effective technique for obtaining samples from pancreatic masses. A new core biopsy needle has been developed by Beacon bnx® (Medtronic, Newton, MA) that allows the possibility to achieve a core for histology evaluation and the interchangibility of needle size using the same needle shelter and different needle sizes.

Detailed Description

At every pass, the material will be fixed in formalin. Three passes will be done. Details of the aspirated material will be described at macroscopic evaluation by the endoscopist and then by the pathologist at macroscopic and microscopic evaluation, in order to find an interobserved agreement on the definition of the core.

Registry
clinicaltrials.gov
Start Date
August 2016
End Date
May 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Istituto Clinico Humanitas
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age greater than 18 and less than 90, both genders..
  • Presence of a pancreatic solid lesion. In the presence of a cystic component, the solid part of the lesion should be more 75% of the total.
  • Absence of an uncorrectable coagulopathy as defined by abnormal prothrombin time (PT) or partial thromboplastin time (PTT) that does not normalize after administration of fresh frozen plasma or coagulation factors.
  • Informed consent is obtained.

Exclusion Criteria

  • Previous biopsy of the lesion with diagnosis of malignancy
  • Presence of an uncorrectable coagulopathy as defined by abnormal prothrombin time (PT) or partial thromboplastin time (PTT) that does not normalize after administration of fresh frozen plasma.
  • Pregnancy or breast-feeding.
  • Patients unable to understand and/or read the consent form.

Outcomes

Primary Outcomes

Core acquisition

Time Frame: 24 h

The presence of a core adequate for histological evaluation for final diagnosis

Study Sites (1)

Loading locations...

Similar Trials